Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 -1.65%
Revenue Growth %: -4.3%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.30, $0.08 better than the analyst estimate of $1.22. Revenue for the quarter came in at $464.2 million versus the consensus estimate of $458.72 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.08-$5.18, versus prior $5.00-$5.15 and the consensus of $5.10.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
- Ciena (CIEN) Tops Q3 EPS by 39c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
